Skip Navigation

Publication Detail

Title: MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.

Authors: Bailey, Sean T; Smith, Aleisha M; Kardos, Jordan; Wobker, Sara E; Wilson, Harper L; Krishnan, Bhavani; Saito, Ryoichi; Lee, Hyo Jin; Zhang, Jing; Eaton, Samuel C; Williams, Lindsay A; Manocha, Ujjawal; Peters, Dorien J; Pan, Xinchao; Carroll, Thomas J; Felsher, Dean W; Walter, Vonn; Zhang, Qing; Parker, Joel S; Yeh, Jen Jen; Moffitt, Richard A; Leung, Janet Y; Kim, William Y

Published In Nat Commun, (2017 Jun 08)

Abstract: Renal carcinoma is a common and aggressive malignancy whose histopathogenesis is incompletely understood and that is largely resistant to cytotoxic chemotherapy. We present two mouse models of kidney cancer that recapitulate the genomic alterations found in human papillary (pRCC) and clear cell RCC (ccRCC), the most common RCC subtypes. MYC activation results in highly penetrant pRCC tumours (MYC), while MYC activation, when combined with Vhl and Cdkn2a (Ink4a/Arf) deletion (VIM), produce kidney tumours that approximate human ccRCC. RNAseq of the mouse tumours demonstrate that MYC tumours resemble Type 2 pRCC, which are known to harbour MYC activation. Furthermore, VIM tumours more closely simulate human ccRCC. Based on their high penetrance, short latency, and histologic fidelity, these models of papillary and clear cell RCC should be significant contributions to the field of kidney cancer research.

PubMed ID: 28593993 Exiting the NIEHS site

MeSH Terms: ADP-Ribosylation Factors/genetics; ADP-Ribosylation Factors/metabolism; Animals; Carcinoma, Renal Cell/genetics*; Carcinoma, Renal Cell/mortality; Carcinoma, Renal Cell/pathology; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16/genetics; Cyclin-Dependent Kinase Inhibitor p16/metabolism; Gene Expression Regulation, Neoplastic; Genes, myc*; Humans; Kidney Neoplasms/genetics*; Kidney Neoplasms/mortality; Kidney Neoplasms/pathology; Mice, Knockout; Mice, Transgenic; Von Hippel-Lindau Tumor Suppressor Protein/genetics*; Von Hippel-Lindau Tumor Suppressor Protein/metabolism; Xenograft Model Antitumor Assays

Back
to Top